Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2022-01-31 00:00:00 ET · period of report 2022-01-27 · accession 0001567619-22-002079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-01-31 | 2022-01-27 | PCSA | Yorke Justin W | Dir | S - Sale | $3.30 | -1,854 | 532.6K | -0.3% | -$6,118 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-27 | S | D | 1,854 | $3.30 | 532,563 | I By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.37, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |